Sanofi Sarclisa Combo Gains Approval as First-line Multiple Myeloma Treatment
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC Speakers
Centessa Pharmaceuticals a New Buy at B Riley on Sleep Disorders Pipeline
Revenues Working Against Bristol-Myers Squibb Company's (NYSE:BMY) Share Price
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
Purple Biotech Says Pancreatic Cancer Study Data Shows CM24 With Nivolumab and Chemo Improves Survival
Bristol Myers Says New Data From Phase 3 DAYBREAK Trial Showed Decreased Rates Of Brain Volume Loss Were Sustained In Open-label Extension For Patients Treated With Zeposia (Ozanimod) For Relapsing Forms Of Multiple Sclerosis
Express News | New Long-Term Zeposia (Ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
Goldman Sachs Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $57
Goldman Sachs analyst Chris Shibutani maintains $Bristol-Myers Squibb(BMY.US)$ with a buy rating, and maintains the target price at $57.According to TipRanks data, the analyst has a success rate of 45
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Bristol-Myers Squibb Analyst Ratings
Multiple pharmaceutical companies are betting on cancer targeted radiotherapy technology, with an investment of about 10 billion US dollars.
Healthcare Glogou September 16th | Several major pharmaceutical companies have already bet on cancer targeted radiotherapy technology - the upcoming therapy that directly delivers radioactive drugs to tumors - which will be the next major breakthrough in cancer treatment. Bristol-Myers Squibb, Astrazeneca, Eli Lilly and Co, and other pharmaceutical companies have spent about $10 billion on acquisitions or collaborations with radioactive drug manufacturers. They are snapping up emerging players in the industry to gain access to technology that can treat multiple types of cancer. Guggenheim Securities
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Bristol-Myers Squibb(BMY.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.4% and a total average
Bristol-Myers Squibb Reports Opdivo, Yervoy Combination's Continued Survival Benefit in Advanced Melanoma
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $52
Wells Fargo analyst Mohit Bansal maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and maintains the target price at $52.According to TipRanks data, the analyst has a success rate of 62.7%